HGH Fragment 176-191 vs SHLP2

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

HGH Fragment 176-191

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Full details →

SHLP2

SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.

Full details →

Side-by-Side Comparison

Aspect	HGH Fragment 176-191	SHLP2
Dose Range	250 mcg–500 mcg	1 mg–5 mg
Frequency	2x daily	1x daily
Cycle Length	12–16 weeks	4–8 weeks
Route	subcutaneous	subcutaneous
Mechanism	Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.	Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways.
Typical Dosage	Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.	Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established.
Administration	Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.	Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties.
Side Effects	Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.	Limited data. Animal studies suggest good tolerability. May affect glucose metabolism.
Best For	Fat Loss	Fat Loss Anti-Aging & Longevity